highly significantp < 0.001
MPH and HPH treatments caused a highly significant reduction in FBS compared to the DOX group ( p < 0.001), indicating dose-dependent glycemic protection ( Fig. 6 ) (see Fig. 6 ). 3.4.
MPH and HPH treatments caused a highly significant reduction in FBS compared to the DOX group ( p < 0.001), indicating dose-dependent glycemic protection ( Fig. 6 ) (see Fig. 6 ). 3.4.